Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor.

Liapi E, Geschwind JF, Vali M, Khwaja AA, Prieto-Ventura V, Buijs M, Vossen JA, Ganapathy-Kanniappan S, Wahl RL.

J Nucl Med. 2011 Feb;52(2):225-30. doi: 10.2967/jnumed.110.083162. Epub 2011 Jan 13. Erratum in: J Nucl Med. 2014 Mar;55(3):521. J Nucl Med. 2011 Mar;52(3):495. J Nucl Med. 2015 May;56(5):797. Ganapathy, Shanmugasudaram [Corrected to Ganapathy-Kanniappan, Shanmugasudaram].

2.

FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model.

Park HS, Chung JW, Jae HJ, Kim YI, Son KR, Lee MJ, Park JH, Kang WJ, Yoon JH, Chung H, Lee K.

Korean J Radiol. 2007 May-Jun;8(3):216-24.

3.

Hepatic intra-arterial injection of 3-bromopyruvate in rabbit VX2 tumor.

Shin SW, Han H, Choo SW, Yoo BC, Park CK, Do YS, Lee JH, Lee DH, Choi D, Choo IW, Kim SS, Lee JY.

Acta Radiol. 2006 Dec;47(10):1036-41.

PMID:
17135005
4.

Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer.

Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C, Geschwind JF.

J Vasc Interv Radiol. 2007 Jan;18(1 Pt 1):95-101.

PMID:
17296709
5.

Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study.

Vali M, Vossen JA, Buijs M, Engles JM, Liapi E, Ventura VP, Khwaja A, Acha-Ngwodo O, Ganapathy-Kanniappan S, Syed L, Wahl RL, Geschwind JF.

J Pharmacol Exp Ther. 2008 Oct;327(1):32-7. doi: 10.1124/jpet.108.141093. Epub 2008 Jun 30. Erratum in: J Pharmacol Exp Ther. 2015 Jun;353(3):560. Shanmugasundaram, Ganapathy [Corrected to Ganapathy-Kanniappan, Shanmugasundaram].

6.

The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model.

Jae HJ, Chung JW, Park HS, Lee MJ, Lee KC, Kim HC, Yoon JH, Chung H, Park JH.

Korean J Radiol. 2009 Nov-Dec;10(6):596-603. doi: 10.3348/kjr.2009.10.6.596.

7.

18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits.

Okuma T, Matsuoka T, Okamura T, Wada Y, Yamamoto A, Oyama Y, Koyama K, Nakamura K, Watanabe Y, Inoue Y.

J Nucl Med. 2006 Aug;47(8):1351-8.

8.

FDG-PET evaluation of therapeutic effects on VX2 liver tumor.

Oya N, Nagata Y, Tamaki N, Takagi T, Murata R, Magata Y, Abe M, Konishi J.

J Nucl Med. 1996 Feb;37(2):296-302.

9.

Changes in 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model.

Song SL, Liu JJ, Huang G, Wang ZH, Song YY, Sun XG, Chen T.

J Nucl Med. 2008 Feb;49(2):303-9. doi: 10.2967/jnumed.107.044206. Epub 2008 Jan 16.

10.

18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.

Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM.

J Nucl Med. 2013 Oct;54(10):1710-6. doi: 10.2967/jnumed.112.119370. Epub 2013 Aug 22.

11.

Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma.

Song MJ, Bae SH, Yoo IeR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK.

World J Gastroenterol. 2012 Jul 7;18(25):3215-22. doi: 10.3748/wjg.v18.i25.3215.

12.
13.

Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization.

Vossen JA, Buijs M, Syed L, Kutiyanwala F, Kutiyanwala M, Geschwind JF, Vali M.

Clin Exp Metastasis. 2008;25(7):811-7. doi: 10.1007/s10585-008-9195-x. Epub 2008 Jul 23.

PMID:
18649116
14.

[Effects of intra-arterial infusion of 3-bromopyruvate on metastases and survival benefit of hepatic VX2 tumor in rabbits].

Jiang XY, Zhang XP, Huang JH, Luo RG, Miao BJ, Wang Y.

Zhonghua Yi Xue Za Zhi. 2013 Oct 22;93(39):3139-42. Chinese.

PMID:
24417996
15.

18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.

Haug AR, Tiega Donfack BP, Trumm C, Zech CJ, Michl M, Laubender RP, Uebleis C, Bartenstein P, Heinemann V, Hacker M.

J Nucl Med. 2012 Mar;53(3):371-7. doi: 10.2967/jnumed.111.096230. Epub 2012 Feb 13.

16.

Evaluation of experimental liver tumors using fluorine-18-2-fluoro-2-deoxy-D-glucose PET.

Oya N, Nagata Y, Ishigaki T, Abe M, Tamaki N, Magata Y, Konishi J.

J Nucl Med. 1993 Dec;34(12):2124-9.

17.

Liposome contrast agent for CT-based detection and localization of neoplastic and inflammatory lesions in rabbits: validation with FDG-PET and histology.

Zheng J, Allen C, Serra S, Vines D, Charron M, Jaffray DA.

Contrast Media Mol Imaging. 2010 May-Jun;5(3):147-54. doi: 10.1002/cmmi.378.

PMID:
20586032
18.

Ferret thoracic anatomy by 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (18F-FDG PET/CT) imaging.

Wu A, Zheng H, Kraenzle J, Biller A, Vanover CD, Proctor M, Sherwood L, Steffen M, Ng C, Mollura DJ, Jonsson CB.

ILAR J. 2012;53(1):E9-21. doi: 10.1093/ilar.53.1.9.

19.

Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.

Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, Dygai-Cochet I, Toubeau M, Humbert O, Coudert B, Fumoleau P, Arnould L, Brunotte F.

J Nucl Med. 2012 Apr;53(4):512-20. doi: 10.2967/jnumed.111.096834. Epub 2012 Feb 17.

20.

[Experimental study of CT guided ³²P-CP-PLLA microparticle implantation in the treatment of rabbit VX2 lung tumor].

Pan D, Yang M, Xu Y, Wang L, Liu L, Huang P.

Zhongguo Fei Ai Za Zhi. 2011 Jan;14(1):1-6. doi: 10.3779/j.issn.1009-3419.2011.01.01. Chinese.

Supplemental Content

Support Center